We monitored their aminotransferase levels, Child-Pugh score, MELD score, HBeAg, HBV DNA level and change of ascites at 3 months, 6
months, 9 months, and 12 months after antiviral treatment. We defined clinical responder as patients with a minimum of 1 point of reduction of Child-Pugh score and decreased ascites or patients with more than 2 points of reduction of Child-Pugh score and virological responder as patients with more than reduction of 2 log10 copies of HBV DNA. Results: Eighty (65%) patients were defined as responder after 12 months of antiviral treatment. Baseline ALT, www.selleckchem.com/products/Trichostatin-A.html HBV DNA and positive rate of HBeAg of responder are higher than that of non-responder. Patients in response group had the significant improvement of Child-Pugh score
(−1.41 ± 1.90, P < 0.001), the remarkable reduction in HBV DNA level (−3.30 ± 1.68 log10 copies/mL, P < 0.001), the decrease of ascites (36.3%, P < 0.001) compared to the findings before treatment. Serum HBV DNA level at 3 months after treatment showed significant difference between response group (−2.74 ± 1.5 log10 copies/mL) and non-response group (−0.31 ± 1.0 log10 copies/mL) (P < 0.001), whereas serum HBV DNA undetectable rate, seroconversion rate and ALT normalization did not. Conclusion: It is possible to predict the clinical and virological response in patients with hepatitis B virus-related liver cirrhosis by checking the reduction in serum HBV DNA level at 3 months after treatment. Key Word(s): 1. Hepatitis B virus; 2. Liver Janus kinase (JAK) Sirolimus chemical structure cirrhosis; 3. Antiviral
treatment; 4. Treatment predictor; Presenting Author: MANEESHA BHULLAR Additional Authors: JOHN YAMBA Corresponding Author: MANEESHA BHULLAR Affiliations: Royal Melbourne Hospital; Ballarat Base Hospital Objective: Peginterferon (PEG-IFN) alpha in combination with ribavirin (RBV) represents the most optimal therapy for chronic hepatitis C. Despite its great efficacy, interferon therapy is associated with a spectrum of side effects. Pulmonary toxicities are a rare side effect which may include interstitial pneumonitis, sarcoidosis, pleuritis, bronchiolitis obliterans organizing pneumonia (BOOP), and exacerbation of asthma. Interstitial pneumonitis is a rare but rapidly progressing and potentially fatal adverse event that has been described. This review describes the classification, epidemiology, natural history, diagnostic criteria and management of Interferon-related interstitial pneumonitis and includes an illustrative patient. Methods: A systematic review of the literature using relevant databases was performed to ascertain patients with chronic hepatitis C who developed interstitial pneumonitis on interferon-based therapy, either as a standalone therapy or in combination with ribavirin.